Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2013; 3(1):26-33. doi:10.7150/thno.4922 This issue Cite

Review

CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential

Ori Wald1,2,3✉, Oz M. Shapira1, Uzi Izhar1

1. Department of Cardiothoracic Surgery, Hadassah University Hospital, Jerusalem, Israel;
2. Goldyne Savad Institute of Gene Therapy, Hadassah University Hospital, Jerusalem, Israel;
3. Laboratory for Surgical Research, Hadassah University Hospital, Jerusalem, Israel.

✉ Corresponding author: Ori Wald M.D, Ph.D. Department of Cardiothoracic Surgery, Hadassah University Hospital, P.O Box 12000, Jerusalem, Israel. FAX: 972-2- 5345125, Phone: 972-50-8946297, e-mail: ori.waldhuji.ac.il.

Citation:
Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential. Theranostics 2013; 3(1):26-33. doi:10.7150/thno.4922. https://www.thno.org/v03p0026.htm
Other styles

File import instruction

Abstract

Lung cancer is the second most common malignancy and the leading cause of cancer-related death in the western world. Moreover, despite advances in surgery, chemotherapy and radiotherapy, the death rate from lung cancer remains high and the reported overall five-year survival rate is only 15%. Thus, novel treatments for this devastating disease are urgently needed. Chemokines, a family of 48 chemotactic cytokines interacts with their 7 transmembrane G-protein-coupled receptors, to guide immune cell trafficking in the body under both physiologic and pathologic conditions. Tumor cells, which express a relatively restricted repertoire of chemokine and chemokine receptors, utilize and manipulate the chemokine system in a manner that benefits both local tumor growth and distant dissemination. Among the 19 chemokine receptors, CXCR4 is the receptor most widely expressed by malignant tumors and whose role in tumor biology is most thoroughly studied. The chemokine CXCL12, which is the sole ligand of CXCR4, is highly expressed in primary lung cancer as well as in the bone marrow, liver, adrenal glands and brain, which are all sites for lung cancer metastasis. This review focuses on the pathologic role of the CXCR4/CXCL12 axis in NSCLC and on the potential therapeutic implication of targeting this axis for the treatment of NSCLC.

Keywords: NSCLC, Lung, Human, Chemokines.

Citation styles

APA
Wald, O., Shapira, O.M., Izhar, U. (2013). CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential. Theranostics, 3(1), 26-33. https://doi.org/10.7150/thno.4922.

ACS
Wald, O.; Shapira, O.M.; Izhar, U. CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential. Theranostics 2013, 3 (1), 26-33. DOI: 10.7150/thno.4922.

NLM
Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential. Theranostics 2013; 3(1):26-33. doi:10.7150/thno.4922. https://www.thno.org/v03p0026.htm

CSE
Wald O, Shapira OM, Izhar U. 2013. CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential. Theranostics. 3(1):26-33.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use